Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0YMJAN
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Anti-PDL1-PBA-Cur
|
|||||
| Synonyms |
Anti-PDL1-PBA-Cur
Click to Show/Hide
|
|||||
| Organization |
Guizhou Provincial People's Hospital; Central South University; South China University of Technology.
|
|||||
| Drug Status |
Investigative
|
|||||
| Antibody Name |
undisclosed
|
|||||
| Antigen Name |
Programmed cell death 1 ligand 1 (CD274)
|
Antigen Info | ||||
| Payload Name |
PBA-Cur
|
Payload Info | ||||
| Therapeutic Target |
Programmed cell death 1 ligand 1 (CD274)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.5196 ug/mL
|
|||
| Method Description |
The in vitro cytotoxicity of anti-PD-L1-PBA-Cur on colon cancer cells was investigated. The HCT116 cells were seeded at a density of 5 × 103 cells/well in a 96-well plate to attach overnight. After co-incubation with 48 h, the cell's viability was investigated using the MTT assay. The cell morphology was further observed using the microscopy.
|
||||
| In Vitro Model | Colon carcinoma | HCT116 cells | CVCL_0291 | ||
References